Preclinical efficacy of clumping factor a in prevention of Staphylococcus aureus infection

mBio

Volumn 7, Issue 1, 2016, Pages

  Li, Xue ^a,b   Wang, Xiaogang ^a   Thompson, Christopher D ^a   Park, Saeyoung ^a,d   Park, Wan Beom ^a,c   Lee, Jean C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^c Seoul National University College of Medicine   (South Korea)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; CLUMPING FACTOR A; FIBRINOGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; MEMBRANE PROTEIN; PHOSPHORYL LIPID A; UNCLASSIFIED DRUG; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CLFA PROTEIN, STAPHYLOCOCCUS AUREUS; COAGULASE; IMMUNOLOGICAL ADJUVANT; PLACEBO; STAPHYLOCOCCUS VACCINE; SUBUNIT VACCINE;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERIAL LOAD; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; KIDNEY ABSCESS; MALE; MOUSE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; OPSONIZATION; OPTIMAL DRUG DOSE; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RAT; SKIN ABSCESS; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS INFECTION; SURGICAL INFECTION; TH17 CELL; ABSCESS; ANIMAL; BLOOD; C57BL MOUSE; IMMUNOLOGY; MICROBIOLOGY; MORTALITY; PRECLINICAL STUDY; SEPSIS; SPRAGUE DAWLEY RAT; STAPHYLOCOCCAL INFECTIONS; SURVIVAL ANALYSIS;

ABSCESS; ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL LOAD; COAGULASE; DRUG EVALUATION, PRECLINICAL; MICE; MICE, INBRED C57BL; PLACEBOS; RATS, SPRAGUE-DAWLEY; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL VACCINES; SURVIVAL ANALYSIS; VACCINES, SUBUNIT;

EID: 84960157790     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02232-15     Document Type: Article

References (61)

1. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339: 520–532. http://dx.doi.org/10.1056/NEJM199808203390806.
2. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, Lessa FC, Lynfield R, Nadle J, Petit S, Ray SM, Schaffner W, Townes J, Fridkin S, Emerging Infections Program_Active Bacterial Core Surveillance MRSA Surveillance Investigators. 2013. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med 173:1970-1978. http://dx.doi.org/10.1001/jamainternmed.2013.10423.
3. Lowy FD. 2003. Antimicrobial resistance: the example of Staphylococcus aureus. J Clin Invest 111:1265–1273. http://dx.doi.org/10.1172/JCI18535.
4. Chambers HF, Deleo FR. 2009. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 7:629–641. http://dx.doi.org/10.1038/nrmicro2200.
5. Smeltzer MS, Lee CY, Harik N, Hart ME, Crossley K, Jefferson K, Archer G, Fowler V. 2009. Molecular basis of pathogenicity, p 65–108. In Crossley KB, Jefferson GL, Archer GL, Fowler VG (ed), Staphylococci in human disease, 2nd ed. Wiley-Blackwell, Oxford, United Kingdom.
6. Foster TJ, Geoghegan JA, Ganesh VK, Höök M. 2014. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus. Nat Rev Microbiol 12:49–62. http://dx.doi.org/10.1038/nrmicro3161.
7. Mazmanian SK, Liu G, Ton-That H, Schneewind O. 1999. Staphylococcus aureus sortase, an enzyme that anchors surface proteins to the cell wall. Science 285:760–763. http://dx.doi.org/10.1126/science.285.5428.760.
8. Kim HK, Cheng AG, Kim HY, Missiakas DM, Schneewind O. 2010. Nontoxigenic protein A vaccine for methicillin-resistant Staphylococcus aureus infections in mice. J Exp Med 207:1863–1870. http://dx.doi.org/10.1084/jem.20092514.
9. McDevitt D, Francois P, Vaudaux P, Foster TJ. 1994. Molecular characterization of the clumping factor (fibrinogen receptor) of Staphylococcus aureus. Mol Microbiol 11:237–248. http://dx.doi.org/10.1111/j.1365-2958.1994.tb00304.x.
10. Moreillon P, Entenza JM, Francioli P, McDevitt D, Foster TJ, François P, Vaudaux P. 1995. Role of Staphylococcus aureus coagulase and clumping factor in pathogenesis of experimental endocarditis. Infect Immun 63:4738–4743.
11. Hair PS, Ward MD, Semmes OJ, Foster TJ, Cunnion KM. 2008. Staphylococcus aureus clumping factor A binds to complement regulator factor I and increases factor I cleavage of C3b. J Infect Dis 198:125–133. http://dx.doi.org/10.1086/588825.
12. Hair PS, Echague CG, Sholl AM, Watkins JA, Geoghegan JA, Foster TJ, Cunnion KM. 2010. Clumping factor A interaction with complement factor I increases C3b cleavage on the bacterial surface of Staphylococcus aureus and decreases complement-mediated phagocytosis. Infect Immun 78:1717–1727. http://dx.doi.org/10.1128/IAI.01065-09.
13. Elkhatib WF, Hair PS, Nyalwidhe JO, Cunnion KM. 2015. New potential role of serum apolipoprotein E mediated by its binding to clumping factor A during Staphylococcus aureus invasive infections to humans. J Med Microbiol 64:335–343. http://dx.doi.org/10.1099/jmm.0.000010.
14. Siboo IR, Cheung AL, Bayer AS, Sullam PM. 2001. Clumping factor A mediates binding of Staphylococcus aureus to human platelets. Infect Immun 69:3120–3127. http://dx.doi.org/10.1128/IAI.69.5.3120-3127.2001.
15. McDevitt D, Nanavaty T, House-Pompeo K, Bell E, Turner N, McIntire L, Foster T, Höök M. 1997. Characterization of the interaction between the Staphylococcus aureus clumping factor (ClfA) and fibrinogen. Eur J Biochem 247:416-424. http://dx.doi.org/10.1111/j.1432-1033.1997.00416.x.
16. McCormack N, Foster TJ, Geoghegan JA. 2014. A short sequence within subdomain N1 of region A of the Staphylococcus aureus MSCRAMM clumping factorAis required for export and surface display. Microbiology 160:659–670. http://dx.doi.org/10.1099/mic.0.074724-0.
17. Thomer L, Becker S, Emolo C, Quach A, Kim HK, Rauch S, Anderson M, Leblanc JF, Schneewind O, Faull KF, Missiakas D. 2014. N-acetylglucosaminylation of serine-aspartate repeat proteins promotes Staphylococcus aureus bloodstream infection. J Biol Chem 289:3478–3486. http://dx.doi.org/10.1074/jbc.M113.532655.
18. Hazenbos WL, Kajihara KK, Vandlen R, Morisaki JH, Lehar SM, Kwakkenbos MJ, Beaumont T, Bakker AQ, Phung Q, Swem LR, Ramakrishnan S, Kim J, Xu M, Shah IM, Diep BA, Sai T, Sebrell A, Khalfin Y, Oh A, Koth C, Lin SJ, Lee BC, Strandh M, Koefoed K, Andersen PS, Spits H, Brown EJ, Tan MW, Mariathasan S. 2013. Novel staphylococcal glycosyltransferases SdgA and SdgB mediate immunogenicity and protection of virulence-associated cell wall proteins. PLoS Pathog 9:e1003653. http://dx.doi.org/10.1371/journal.ppat.1003653.
19. Josefsson E, Hartford O, O’Brien L, Patti JM, Foster T. 2001. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant. J Infect Dis 184: 1572–1580. http://dx.doi.org/10.1086/324430.
20. McAdow M, Kim HK, Dedent AC, Hendrickx AP, Schneewind O, Missiakas DM. 2011. Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood. PLoS Pathog 7:e1002307. http://dx.doi.org/10.1371/journal.ppat.1002307.
21. Kwiecinski J, Jin T, Josefsson E. 2014. Surface proteins of Staphylococcus aureus play an important role in experimental skin infection. APMIS 122: 1240–1250. http://dx.doi.org/10.1111/apm.12295.
22. Josefsson E, Higgins J, Foster TJ, Tarkowski A. 2008. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence. PLoS One 3:e2206. http://dx.doi.org/10.1371/journal.pone.0002206.
23. Flick MJ, Du X, Prasad JM, Raghu H, Palumbo JS, Smeds E, Höök M, Degen JL. 2013. Genetic elimination of the binding motif on fibrinogen for the S. aureus virulence factor ClfA improves host survival in septicemia. Blood 121:1783–1794. http://dx.doi.org/10.1182/blood-2012-09-453894.
24. Narita K, Hu DL, Mori F, Wakabayashi K, Iwakura Y, Nakane A. 2010. Role of interleukin-17A in cell-mediated protection against Staphylococcus aureus infection in mice immunized with the fibrinogen-binding domain of clumping factor A. Infect Immun 78:4234-4242. http://dx.doi.org/10.1128/IAI.00447-10.
25. Stranger-Jones YK, Bae T, Schneewind O. 2006. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 103: 16942–16947. http://dx.doi.org/10.1073/pnas.0606863103.
26. Lattar SM, Noto Llana M, Denoël P, Germain S, Buzzola FR, Lee JC, Sordelli DO. 2014. Protein antigens increase the protective efficacy of a capsule-based vaccine against Staphylococcus aureus in a rat model of osteomyelitis. Infect Immun 82:83–91. http://dx.doi.org/10.1128/IAI.01050-13.
27. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, Jung E, Millard D, Schelonka R, Eyal F, Morris A, Kapik B, Roberson D, Kesler K, Patti J, Hetherington S. 2007. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr 151:260-265. http://dx.doi.org/10.1016/j.jpeds.2007.04.060.
28. Otto M. 2010. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther 10:1049–1059. http://dx.doi.org/10.1517/14712598.2010.495115.
29. Weems JJ, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, Winston L, John JF, Kubin CJ, Talwani R, Moore T, Patti JM, Hetherington S, Texter M, Wenzel E, Kelley VA, Fowler VG. 2006. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50: 2751–2755. http://dx.doi.org/10.1128/AAC.00096-06.
30. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, Corey GR, Carmeli Y, Betts R, Hartzel JS, Chan IS, McNeely TB, Kartsonis NA, Guris D, Onorato MT, Smugar SS, DiNubile MJ, Sobanjo-ter Meulen A. 2013. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA 309:1368-1378. http://dx.doi.org/10.1001/jama.2013.3010.
31. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, Yeoh H, Law D, Robbins JB, Schneerson R, Muenz L, Fuller S, Johnson J, Fireman B, Alcorn H, Naso R. 2002. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med 346: 491–496. http://dx.doi.org/10.1056/NEJMoa011297.
32. Nissen M, Marshall H, Richmond P, Shakib S, Jiang Q, Cooper D, Rill D, Baber J, Eiden J, Gruber W, Jansen KU, Emini EA, Anderson AS, Zito ET, Girgenti D. 2015. A randomized phase I study of the safety and immunogenicity of three ascending dose levels of a 3-antigen Staphylococcus aureus vaccine (SA3Ag) in healthy adults. Vaccine 33:1846-1854. http://dx.doi.org/10.1016/j.vaccine.2015.02.024.
33. Levy J, Licini L, Haelterman E, Moris P, Lestrate P, Damaso S, Van Belle P, Boutriau D. 2015. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: results of a randomized phase I trial. Hum Vaccin Immunother 11:620–631. http://dx.doi.org/10.1080/21645515.2015.1011021.
34. Scully IL, Timofeyeva Y, Keeney D, Matsuka YV, Severina E, McNeil LK, Nanra J, Hu G, Liberator PA, Jansen KU, Anderson AS. 2015. Demonstration of the preclinical correlate of protection for Staphylococcus aureus clumping factor A in a murine model of infection. Vaccine 33: 5452–5457. http://dx.doi.org/10.1016/j.vaccine.2015.08.029.
35. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, Fu Y, French SW, Edwards JE, Jr, Spellberg B. 2009. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703. http://dx.doi.org/10.1371/journal.ppat.1000703.
36. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, Magorien JE, Blauvelt A, Kolls JK, Cheung AL, Cheng G, Modlin RL, Miller LS. 2010. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest 120:1762–1773. http://dx.doi.org/10.1172/JCI40891.
37. Wacker M, Wang L, Kowarik M, Dowd M, Lipowsky G, Faridmoayer A, Shields K, Park S, Alaimo C, Kelley KA, Braun M, Quebatte J, Gambillara V, Carranza P, Steffen M, Lee JC. 2014. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 209:1551–1561. http://dx.doi.org/10.1093/infdis/jit800.
38. Watts A, Ke D, Wang Q, Pillay A, Nicholson-Weller A, Lee JC. 2005. Staphylococcus aureus strains that express serotype 5 or serotype 8 capsular polysaccharides differ in virulence. Infect Immun 73:3502–3511. http://dx.doi.org/10.1128/IAI.73.6.3502-3511.2005.
39. Thakker M, Park J-S, Carey V, Lee JC. 1998. Staphylococcus aureus serotype 5 capsular polysaccharide is antiphagocytic and enhances bacterial virulence in a murine bacteremia model. Infect Immun 66:5183–5189.
40. Nanra JS, Buitrago SM, Crawford S, Ng J, Fink PS, Hawkins J, Scully IL, McNeil LK, Aste-Amézaga JM, Cooper D, Jansen KU, Anderson AS. 2013. Capsular polysaccharides are an important immune evasion mechanism for Staphylococcus aureus. Hum Vaccin Immunother 9:480–487. http://dx.doi.org/10.4161/hv.23223.
41. Nanra JS, Timofeyeva Y, Buitrago SM, Sellman BR, Dilts DA, Fink P, Nunez L, Hagen M, Matsuka YV, Mininni T, Zhu D, Pavliak V, Green BA, Jansen KU, Anderson AS. 2009. Heterogeneous in vivo expression of clumping factor A and capsular polysaccharide by Staphylococcus aureus: implications for vaccine design. Vaccine 27:3276–3280. http://dx.doi.org/10.1016/j.vaccine.2009.01.062.
42. Timofeyeva Y, Scully IL, Anderson AS. 2014. Immunofluorescence microscopy for the detection of surface antigens in methicillin-resistant Staphylococcus aureus (MRSA). Methods Mol Biol 1085:85–95. http://dx.doi.org/10.1007/978-1-62703-664-1_4.
43. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG. 2011. The pathogenesis of sepsis. Annu Rev Pathol 6:19–48. http://dx.doi.org/10.1146/annurev-pathol-011110-130327.
44. Linde H, Wagenlehner F, Strommenger B, Drubel I, Tanzer J, Reischl U, Raab U, Höller C, Naber KG, Witte W, Hanses F, Salzberger B, Lehn N. 2005. Healthcare-associated outbreaks and community-acquired infections due to MRSA carrying the Panton-Valentine leucocidin gene in southeastern Germany. Eur J Clin Microbiol Infect Dis 24:419-422. http://dx.doi.org/10.1007/s10096-005-1341-7.
45. Héraïef E, Glauser MP, Freedman LR. 1982. Natural history of aortic valve endocarditis in rats. Infect Immun 37:127–131.
46. Patti JM. 2004. A humanized monoclonal antibody targeting Staphylococcus aureus. Vaccine 22(Suppl 1):S39-S43. http://dx.doi.org/10.1016/j.vaccine.2004.08.015.
47. Lindblad EB. 2000. Freund’s adjuvants, p 49–63. In O’Hagan DT (ed), Vaccine adjuvants: preparation methods and research protocols. Humana Press, Inc, Totowa, NJ.
48. Vernachio J, Bayer AS, Le T, Chai YL, Prater B, Schneider A, Ames B, Syribeys P, Robbins J, Patti JM. 2003. Anti-clumping factor A immunoglobulin reduces the duration of methicillin-resistant Staphylococcus aureus bacteremia in an experimental model of infective endocarditis. Antimicrob Agents Chemother 47:3400-3406. http://dx.doi.org/10.1128/AAC.47.11.3400-3406.2003.
49. Deivanayagam CC, Wann ER, Chen W, Carson M, Rajashankar KR, Höök M, Narayana SV. 2002. A novel variant of the immunoglobulin fold in surface adhesins of Staphylococcus aureus: crystal structure of the fibrinogen-binding MSCRAMM, clumping factor A. EMBO J 21: 6660–6672. http://dx.doi.org/10.1093/emboj/cdf619.
50. Murphy E, Lin SL, Nunez L, Andrew L, Fink PS, Dilts DA, Hoiseth SK, Jansen KU, Anderson AS. 2011. Challenges for the evaluation of Staphylococcus aureus protein based vaccines: monitoring antigenic diversity. Hum Vaccin 7(Suppl):51–59. http://dx.doi.org/10.4161/hv.7.0.14562.
51. Stegger M, Price LB, Larsen AR, Gillece JD, Waters AE, Skov R, Andersen PS. 2012. Genome sequence of Staphylococcus aureus strain 11819-97, an ST80-IV European community-acquired methicillinresistant isolate. J Bacteriol 194:1625–1626. http://dx.doi.org/10.1128/JB.06653-11.
52. Brady RA, Mocca CP, Burns DL. 2013. Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants. Clin Vaccine Immunol 20:1338–1340. http://dx.doi.org/10.1128/CVI.00275-13.
53. Schulz H, Hennecke H, Thöny-Meyer L. 1998. Prototype of a heme chaperone essential for cytochrome c maturation. Science 281:1197–1200. http://dx.doi.org/10.1126/science.281.5380.1197.
54. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194:1761–1770. http://dx.doi.org/10.1086/509506.
55. Duthie ES, Lorenz LL. 1952. Staphylococcal coagulase: mode of action and antigenicity. J Gen Microbiol 6:95–107. http://dx.doi.org/10.1099/00221287-6-1-2-95.
56. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
57. Hawkins J, Kodali S, Matsuka YV, McNeil LK, Mininni T, Scully IL, Vernachio JH, Severina E, Girgenti D, Jansen KU, Anderson AS, Donald RG. 2012. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure. Clin Vaccine Immunol 19:1641–1650. http://dx.doi.org/10.1128/CVI.00354-12.
58. Portolés M, Kiser KB, Bhasin N, Chan KH, Lee JC. 2001. Staphylococcus aureus Cap5O has UDP-ManNAc dehydrogenase activity and is essential for capsule expression. Infect Immun 69:917–923. http://dx.doi.org/10.1128/IAI.69.2.917-923.2001.
59. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, Tzianabos AO, Lee JC. 2006. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A 103:10408–10413. http://dx.doi.org/10.1073/pnas.0508961103.
60. Lee JC, Betley MJ, Hopkins CA, Perez NE, Pier GB. 1987. Virulence studies, in mice, of transposon-induced mutants of Staphylococcus aureus differing in capsule size. J Infect Dis 156:741–750. http://dx.doi.org/10.1093/infdis/156.5.741.
61. Lee JC, Park JS, Shepherd SE, Carey V, Fattom A. 1997. Protective efficacy of antibodies to the Staphylococcus aureus type 5 capsular polysaccharide in a modified model of endocarditis in rats. Infect Immun 65: 4146–4151.